Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen☆
To access this article, please choose from the options below
☆ This study was supported by an unrestricted grant from Bayer Schering Pharma AG, Berlin, Germany.
PII: S0010-7824(09)00037-7
doi:10.1016/j.contraception.2009.01.016
© 2009 Elsevier Inc. All rights reserved.
